ArticleBiochimica et biophysica acta2016
BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity.
Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Dynamic Alterations of BMP9 in NAFLD: A Novel Hepatokine Marker of Metabolic Dysfunction and Disease Severity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside.Protein & cell · 2025Review
- Distinct signalling dynamics of BMP4 and BMP9 in brown versus white adipocytes.Scientific reports · 2025Article
- Brown adipose tissue: a potential target for aging interventions and healthy longevity.Biogerontology · 2024Review
- Unveiling the Impact of BMP9 in Liver Diseases: Insights into Pathogenesis and Therapeutic Potential.Biomolecules · 2024Review
- Review
- Molecular and cellular regulation of thermogenic fat.Frontiers in endocrinology · 2023Review
- Factors Associated with White Fat Browning: New Regulators of Lipid Metabolism.International journal of molecular sciences · 2022Review
- Circulating Bone Morphogenetic Protein-9 is Decreased in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease.International journal of general medicine · 2022Article
- New insights into BMP9 signaling in liver diseases.Molecular and cellular biochemistry · 2021Review
- Endocrine role of bone in the regulation of energy metabolism.Bone research · 2021Review
- Natural Bioactive Compounds as Potential Browning Agents in White Adipose Tissue.Pharmaceutical research · 2021Review
- Potential Functions of the BMP Family in Bone, Obesity, and Glucose Metabolism.Journal of diabetes research · 2021Review
- Distinct Murine Pancreatic Transcriptomic Signatures during Chronic Pancreatitis Recovery.Mediators of inflammation · 2021Article
- Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis.Journal of physiology and biochemistry · 2020Review
- CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression.Science advances · 2020Article
- Adenovirus‑mediated overexpression of bone morphogenetic protein‑9 promotes methionine choline deficiency‑induced non‑alcoholic steatohepatitis in non‑obese mice.Molecular medicine reports · 2019Article
- Brown and Beige Adipose Tissue and Aging.Frontiers in endocrinology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Although BMP-9 has been reported to induce browning of white adipose tissues (WATs) and suppress high fat diet-induced obesity, detailed molecular mechanism needs to be further elucidated. We report here that administration of MB109, a recombinant derivative of human BMP-9, into obese mice enhanced gene expression of fibroblast growth factor 21 (FGF21), a metabolic regulator, and alleviates a spectrum of pathological symptoms due to high fat diet-induced obesity. In addition, periodical injection of MB109 (500μg/kg/week) reduced an amount of lipid droplets in the liver, serum levels of alanine aminotransferase (ALT), and total cholesterol. These results indicate that MB109 is also effective to treat obesity-mediated non-alcoholic fatty liver disease (NAFLD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.